Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back

Akronym

BOUNCE

Bidragets beskrivning

Coping with breast cancer more and more becomes a major socio-economic challenge not least due to its constantly increasing incidence in the developing world. There is a growing need for novel strategies to improve understanding and capacity to predict resilience of women to the variety of stressful experiences and practical challenges related to breast cancer. This is a necessary step toward efficient recovery through personalized interventions. BOUNCE will bring together modeling, medical, and social sciences experts to advance current knowledge on the dynamic nature of resilience as it relates to efficient recovery from breast cancer. BOUNCE will take into consideration clinical, cancer-related biological, lifestyle, and psychosocial parameters in order to predict individual resilience trajectories throughout the cancer continuum and eventually increase resilience in breast cancer survivors and help them remain in the workforce and enjoy a better quality of life. BOUNCE will deliver a unified clinical model of modifiable factors associated with optimal disease outcomes and will deploy a prospective multi-center clinical pilot at four major oncology centers (in Italy, Finland, Israel and Portugal), where a total of 660 women will be recruited in order to assess its clinical validity against crucial patient outcomes (illness progression, wellbeing, and functionality). The advanced computational tools to be employed will validate indices of patients’ capacity to bounce back during the highly stressful treatment and recovery period following diagnosis of breast cancer. The overreaching goal of BOUNCE is to incorporate elements of a dynamic, predictive model of patient outcomes in building a decision-support system used in routine clinical practice to provide physicians and other health professionals with concrete, personalized recommendations regarding optimal psychosocial support strategies.
Visa mer

Startår

2017

Slutår

2022

Beviljade finansiering

NHG FINLAND OY
747 435 €
Participant
NOONA HEALTHCARE OY
364 250 €
Participant
NHG CONSULTING OY
747 435 €
Participant
FUNDACAO D. ANNA SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD (PT)
497 000 €
Participant
SINGULARLOGIC ANONYMI ETAIREIA PLIROFORIAKON SYSTIMATON KAI EFARMOGON PLIROFORIKIS (EL)
448 125 €
Participant
INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS (EL)
487 500 €
Participant
ISTITUTO EUROPEO DI ONCOLOGIA SRL (IT)
385 600 €
Participant
THE HEBREW UNIVERSITY OF JERUSALEM (IL)
557 000 €
Participant
IDRYMA TECHNOLOGIAS KAI EREVNAS (EL)
738 875 €
Participant

Beviljat belopp

4 999 410 €

Finansiär

Europeiska unionen

Typ av finansiering

Research and Innovation action

Ramprogram

Horizon 2020 Framework Programme

Utlysning

Programdel
Health (5290)
Methods and data (5305)
Tema
Personalised computer models and in-silico systems for well-being (SC1-PM-17-2017)
Utlysnings ID
H2020-SC1-2017-CNECT-2

Övriga uppgifter

Finansieringsbeslutets nummer

777167

Identifierade teman

cancer